本研究使用可生物降解聚己内酯（PCL）作为潜在的非小细胞肺癌（NSCLC）可吸入载体，开发并评估了索拉非尼替硫氨酸盐（SRT）载药的聚合物微粒（MPs）。MPs是通过喷雾干燥油包水（o/w）乳液制备的。优化后的MPs具有良好的流动性，粒径为2.84±0.5μm，电位为-14.0±1.5mV，包封效率为85.08±5.43％。ATR-FTIR/DSC研究表明，晶态药物的特征性峰缺失，表明药物包封良好。在扫描电子显微镜（SEM）照片中，MPs呈现出球状和均匀的形态。MPs显示出72小时内的双相释放模式。安德森级联撞击器（ACI）的研究表明，药物在第4级沉积最多，说明MPs可以达到肺部的次级和终末支气管。可吸入MPs具有良好的空气动力学特性，质量中值空气动力学直径（MMAD）为2.63±1.3μm，几何标准差（GSD）为1.93±0.2μm，细颗粒分数（FPF）为87±2.5％。最后，在A549肺癌细胞的细胞毒性研究中，MPs的IC50值为0.6011±0.8μM，比游离药物低了85.68％。这些发现表明基于PCL的SRT载药可吸入微粒是一种新型NSCLC治疗方法。

The study developed and evaluated Sorafenib Tosylate (SRT)-loaded polymeric microparticles (MPs) using biodegradable polymer polycaprolactone (PCL) as a potential inhalable carrier for NSCLC. MPs were prepared by spray-drying an oil-in-water (o/w) emulsion. The optimized MPs demonstrated excellent flowability, particle size of 2.84 ± 0.5 μm, zeta potential of -14.0 ± 1.5 mV, and 85.08 ± 5.43% entrapment efficiency. ATR-FTIR/DSC studies revealed a lack of characteristic peaks of the crystalline drug signifying good entrapment of the drug. MPs were spherical and uniform in SEM pictures. The MPs showed a biphasic release pattern up to 72h. The Anderson cascade impactor (ACI) investigation demonstrated the highest drug deposition at stage 4, which revealed that the MPs can reach the lungs' secondary and terminal bronchi. Inhalable MPs had an efficient aerodynamic property with a mass median aerodynamic diameter (MMAD) of 2.63 ± 1.3 μm, a geometric standard deviation (GSD) of 1.93 ± 0.2 μm, and a fine particle fraction (FPF) of 87 ± 2.5%. Finally, in cytotoxicity studies on A549 cancer cells, MPs had an IC50 value of 0.6011 ± 0.8 μM, which was 85.68% lower than free drug. These findings suggest SRT-loaded inhalable PCL-based MPs as a novel NSCLC treatment.